Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: RJMC who wrote (3816)	1/29/2001 4:09:25 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

I'm unaware of any specific new information on the patients in San Antonio, but I believe the trial will not continue much longer, and ASCO should provide the opportunity to present a final report. I agree that Orphan Drug Status was to be expected, but now that it's a fact it should expedite approval, and hopefully signals the fact that in Phase II and beyond Pancreatic Cancer will be in a trial of its own. This should permit data to be accrued much more rapidly. Gary